| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Abe, O, et al.
(författare)
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
- 2005
-
Ingår i: The Lancet. - 1474-547X. ; 365:9472, s. 1687-1717
-
Tidskriftsartikel (refereegranskat)abstract
- Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
|
|
| 6. |
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Morishita, Y., et al.
(författare)
-
Direct observation of the initial-state distribution of the first electron transferred to slow highly charged ions interacting with a metal surface
- 2004
-
Ingår i: Physical Review A (Atomic, Molecular and Optical Physics). - 1050-2947. ; 70:1
-
Tidskriftsartikel (refereegranskat)abstract
- The electron transfer process in the interaction of a slow highlycharged ion with a metal surface has been studied employing amicrocapillary foil as a target. The combination of the target and avisible light spectroscopy allows us to directly evaluate the initial(n,ℓ) distributions of the first transferred electrons. It wasfound that observed lines were primarily attributed to Δn=1transitions with relatively high angular momenta ( ℓi≳4 ) . A cascade analysis revealed that the electron is selectivelytransferred to n≈ qin +1 states with a narrowdistribution width of δn≈2 (full width at half maximum). Theaverage initial principal quantum number is consistent with theprediction of the classical over-barrier model.
|
|
| 11. |
- Morishita, Y, et al.
(författare)
-
Visible light spectroscopy of Ar6+ ions in high Rydberg states produced with a microcapillary target
- 2003
-
Ingår i: Nuclear Instruments & Methods in Physics Research. Section B: Beam Interactions with Materials and Atoms. - 0168-583X. ; 205, s. 758-761
-
Tidskriftsartikel (refereegranskat)abstract
- We have observed photons in the visible light range emitted from slow (2.0 keV/amu) highly charged Ar6+ ions which have captured one electron and transmitted through a Ni microcapillary target. Observed lines were identified by comparing with an ab initio calculation based on the multi-configuration Hartree-Fock method. (C) 2003 Elsevier Science B.V. All rights reserved.
|
|
| 12. |
|
|
| 13. |
|
|
| 14. |
|
|
| 15. |
|
|
| 16. |
- Welch, Brian, et al.
(författare)
-
JWST Imaging of Earendel, the Extremely Magnified Star at Redshift z=6.2
- 2022
-
Ingår i: Astrophysical Journal Letters. - : Institute of Physics (IOP). - 2041-8205 .- 2041-8213. ; 940
-
Tidskriftsartikel (refereegranskat)abstract
- The gravitationally lensed star WHL 0137-LS, nicknamed Earendel, was identified with a photometric redshift z (phot) = 6.2 +/- 0.1 based on images taken with the Hubble Space Telescope. Here we present James Webb Space Telescope (JWST) Near Infrared Camera images of Earendel in eight filters spanning 0.8-5.0 mu m. In these higher-resolution images, Earendel remains a single unresolved point source on the lensing critical curve, increasing the lower limit on the lensing magnification to mu > 4000 and restricting the source plane radius further to r < 0.02 pc, or similar to 4000 au. These new observations strengthen the conclusion that Earendel is best explained by an individual star or multiple star system and support the previous photometric redshift estimate. Fitting grids of stellar spectra to our photometry yields a stellar temperature of T (eff) similar to 13,000-16,000 K, assuming the light is dominated by a single star. The delensed bolometric luminosity in this case ranges from log(L)=5.8 L-theta, which is in the range where one expects luminous blue variable stars. Follow-up observations, including JWST NIRSpec scheduled for late 2022, are needed to further unravel the nature of this object, which presents a unique opportunity to study massive stars in the first billion years of the universe.
|
|
| 17. |
- Roszjar, J., et al.
(författare)
-
Chemical, microstructural and chronological record of phosphates in the Ksar Ghilane 002 enriched shergottite
- 2019
-
Ingår i: Geochimica et Cosmochimica Acta. - 0016-7037 .- 1872-9533. ; 245, s. 385-405
-
Tidskriftsartikel (refereegranskat)abstract
- The enriched basaltic (martian) shergottite Ksar Ghilane (KG) 002, discovered in 2010, is exceptionally rich in coexisting but discrete apatite and merrillite crystals. It has been selected to better constrain the formation conditions and post-crystallization processes, and thus the evolution of martian rocks based on Ca-phosphates. A petrological, chemical, chronological and microstructural approach using a series of high-spatial resolution techniques including Raman spectroscopy, electron microscopy (SEM, EPMA, CL-imaging) and secondary ion mass spectrometry (SIMS) analysis has been applied to a representative number of Ca-phosphate grains. Analytical results for apatite and merrillite reveal: (i) zoning in F, Cl, Br and I concentrations, (ii) elevated Cl concentrations in the range of ∼11,900–35,300 µg/g and halogen ratios, i.e., Cl/Br and Cl/I, as well as stable chlorine isotope composition, reported as δ37Cl values rel. to Standard Mean Ocean Chloride (SMOC, defined as 0‰) with a value of +0.67 ± 0.14‰ (1σ), distinguishing KG 002 phosphates from that of other enriched and depleted shergottites. The halogen and heavier δ37Cl record indicate a slightly higher degree of ∼3.5% assimilation of Cl-rich and isotopically heavier crustal reservoir on Mars when compared to other enriched shergottites. (iii) Structural investigations together with the chemical and petrological context of the grains confirm the occurrence of hydroxyl-poor merrillite, indicate weak if any alteration effects induced by metamictization, only minor structural modifications due to shock metamorphism, and absence of replacement reactions. Therefore, igneous crystallization of Ca-phosphates from a fractionated, hydrous and ferrous mantle source, rich in volatiles including the halogens and Na and lithophile rare earth-elements, and absence of interaction with crustal fluids/brines of the sample is deduced. (iv) The Pb isotopic composition of six apatite and three merrillite grains is highly unradiogenic and the 238U-206Pb record yields a phosphate crystallization time at 395 ± 240 Ma (2σ), which is similar to those of other enriched shergottites.
|
|
| 18. |
- Sakurai, T., et al.
(författare)
-
RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma
- 2016
-
Ingår i: Oncogene. - : Springer Science and Business Media LLC. - 0950-9232 .- 1476-5594. ; 35:38, s. 5000-5009
-
Tidskriftsartikel (refereegranskat)abstract
- RNA-binding proteins provide a new layer of posttranscriptional regulation of RNA during cancer progression. We identified RNA-binding motif protein 47 (RBM47) as a target gene of transforming growth factor (TGF)-beta in mammary gland epithelial cells (NMuMG cells) that have undergone the epithelial-to-mesenchymal transition. TGF-beta repressed RBM47 expression in NMuMG cells and lung cancer cell lines. Expression of RBM47 correlated with good prognosis in patients with lung, breast and gastric cancer. RBM47 suppressed the expression of cell metabolism-related genes, which were the direct targets of nuclear factor erythroid 2-related factor 2 (Nrf2; also known as NFE2L2). RBM47 bound to KEAP1 and Cullin 3 mRNAs, and knockdown of RBM47 inhibited their protein expression, which led to enhanced binding of Nrf2 to target genomic regions. Knockdown of RBM47 also enhanced the expression of some Nrf2 activators, p21/CDKN1A and MafK induced by TGF-beta. Both mitochondrial respiration rates and the side population cells in lung cancer cells increased in the absence of RBM47. Our findings, together with the enhanced tumor formation and metastasis of xenografted mice by knockdown of the RBM47 expression, suggested tumor-suppressive roles for RBM47 through the inhibition of Nrf2 activity.
|
|
| 19. |
- Sanada, F, et al.
(författare)
-
Activated Factor X Induces Endothelial Cell Senescence Through IGFBP-5
- 2016
-
Ingår i: Scientific reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 6, s. 35580-
-
Tidskriftsartikel (refereegranskat)abstract
- Uncontrolled coagulation contributes to the pathophysiology of several chronic inflammatory diseases. In these conditions, senescent cells are often observed and is involved in the generation of inflammation. The coincidence of hyper-coagulation, cell senescence, and inflammation suggests the existence of a common underlying mechanism. Recent evidence indicates that activated coagulation factor X (FXa) plays a role in the processes beyond blood coagulation. This non-hematologic function entails the mediation of inflammation and tissue remodeling. We therefore tested the hypothesis that FXa induces cell senescence resulting in tissue inflammation and impaired tissue regeneration. Human umbilical vein endothelial cells were stimulated with FXa for 14 days. The proliferation of cells treated with FXa was significantly smaller, and the fraction of senescence-associated β-galactosidase-positive cells was increased as compared to the control group. RT-qPCR array revealed that FXa increased the expression of IGFBP-5, EGR-1, p53, and p16INK4a. Inhibition of FXa by a direct FXa inhibitor, rivaroxaban, or IGFBP-5 by siRNA decreased FXa-induced cell senescence, restoring cell proliferation. Moreover, in an ischemic hind limb mouse model, FXa inhibited neovascularization by endothelial progenitor cell. However, rivaroxaban significantly restored FXa-induced impaired angiogenesis. In summary, FXa induced endothelial cell senescence through IGFBP-5, resulting in impaired angiogenesis.
|
|
